Drug Targets in Prostate Cancer: An Appetite for KLK2-Mediated Destruction.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 40924642.
- Also identified by DOI 10.1158/1078-0432.CCR-25-2546 and PMC identifier 12469817.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Human kallikrein (KLK) 2 is a prostate cancer tissue-specific protein that is regulated by androgen receptor signaling. KLK2 was not previously recognized as a therapeutic target as it was shown to be a secreted serine protease with no evidence for localization to the cell surface. It has now been demonstrated that KLK2 is expressed on the cell surface and is targetable by various methodologies. See related article by Shen et al., p. 4543.
Medical subject headings
- Prostatic Neoplasms
- Kallikreins
- Tissue Kallikreins